Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Systems in depth

One section per system: its state at evidence close, its exposures and what the operational series will watch.

10 min read0 figures5 tables25 notesNR-XTECH-SYNBIO-GLOBAL-2026-BASELINE

अनुक्रमणिका
  1. ·Edition home
  2. ·Executive summary
  3. 1Synthetic biology is a build capability and a governance test
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Design capability outpaces screening and oversight
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
    1. 8.1 Genome, circuit and protein design platforms
    2. 8.2 Energy, water and feedstock for biomanufacturing
    3. 8.3 DNA, instruments and manufacturing capacity
    4. 8.4 Economy, investment and workforce
    5. 8.5 Biosecurity and governance watch
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

8.1Genome, circuit and protein design platforms

Biological design now spans whole genomes, genetic circuits and designed proteins. Evidence is strongest where peer review exists and weakest for industrial performance.

57codons

Syn57 genetic code2

60circuits

built by one design tool, 20166

6.5chromosomes

synthetic yeast in one strain4

Table 8.1State at baseline
घटकस्थितीपुरावास्थिती
Recoded bacterial genomesa 57-codon code reported in 2025; 61 codons in 2019123नोंदवलेले
Synthetic yeastsix and a half chromosomes combined in one strain443नोंदवलेले
Circuit design software45 of 60 circuits worked in every output state6नोंदवलेले
Protein design softwaregenerative binder design tested by structure7नोंदवलेले

Couplings

  • AIC → BIO design tools
  • DAT → BIO sequence data
  • FIN → BIO funding

Evidence to bind in 2027

  • industrial performance of engineered strains
  • cost of genome synthesis

Related editions

  • GLB Global Systems
  • GS-04 Health and One Health
  • GS-03 Food and Agrifood Systems
  • XT-05 Genomics and Gene Editing
  • SR-08 Health Security, One Health and Biosecurity
  • XT-01 Artificial Intelligence and Agentic Systems

8.2Energy, water and feedstock for biomanufacturing

Fermentation and cell-free production need energy, process water and sugar or other feedstock. No source read counts them on a common basis.

0figures

bound for energy, water and feedstock in this edition

25awards

US planning awards for bioindustrial plants, 202424

87USD million

US institute award over seven years23

Table 8.2State at baseline
घटकस्थितीपुरावास्थिती
Process energynot published on a common basis; no figure used24Expert input
Process waternot published on a common basis; no figure used24Expert input
Feedstockdemand not bound; no figure used from economy-level reports37Expert input
Siting and planningUS awards fund plant planning, not construction24नोंदवलेले

Couplings

  • ENE ↔ BIO process energy
  • WAT → BIO process water
  • FOO → BIO feedstock

Evidence to bind in 2027

  • energy, water and feedstock per tonne of product
  • plant counts and utilisation

Related editions

  • GLB Global Systems
  • GS-04 Health and One Health
  • GS-03 Food and Agrifood Systems
  • XT-05 Genomics and Gene Editing
  • SR-08 Health Security, One Health and Biosecurity
  • XT-01 Artificial Intelligence and Agentic Systems

8.3DNA, instruments and manufacturing capacity

The build base starts with synthesised DNA, instruments and reagents and ends in pilot and commercial plants. Public sources count programmes more than capacity.

332.8USD million

Twist Bioscience revenue, nine months to 30 June 202616

48%

share of Twist third-quarter revenue from DNA synthesis and protein solutions, derived16

42USD million

US planning awards to September 202424

Table 8.3State at baseline
घटकस्थितीपुरावास्थिती
DNA synthesisone provider reports USD 56.6 million for the segment in one quarter16नोंदवलेले
Instruments and reagentsdependence not documented in the sources read36Expert input
InstituteUSD 87 million over seven years for a manufacturing institute23नोंदवलेले
Plant capacitynot counted in the sources read24Expert input

Couplings

  • MIN → BIO reagents
  • TRD → BIO export controls
  • FIN → INF plants

Evidence to bind in 2027

  • synthesis capacity by provider and country
  • instrument and reagent dependence

Related editions

  • GLB Global Systems
  • GS-04 Health and One Health
  • GS-03 Food and Agrifood Systems
  • XT-05 Genomics and Gene Editing
  • SR-08 Health Security, One Health and Biosecurity
  • XT-01 Artificial Intelligence and Agentic Systems

8.4Economy, investment and workforce

Company results are mixed and the sector has no common investment series. Workforce numbers are the thinnest part of the evidence.

170.2USD million

Ginkgo Bioworks revenue, 202517

227.0USD million

Ginkgo Bioworks revenue, 202417

15USD billion

minimum funding recommended by a US commission14

Table 8.4State at baseline
घटकस्थितीपुरावास्थिती
Company revenueGinkgo fell about 25% in 2025; Twist guided to USD 456 to 457 million for fiscal 20261617नोंदवलेले
Public programmesUS commission recommends at least USD 15 billion over five years; a recommendation14नोंदवलेले
Bioeconomy sizecommentary cites over USD 210 billion of US GDP; secondary figure15नोंदवलेले
Workforceskills gaps reported in policy; no figure bound14Expert input

Couplings

  • FIN → BIO scale-up
  • HLT → BIO clinical demand
  • FIN → INF plants

Evidence to bind in 2027

  • investment on a common basis
  • workforce size and skills gaps

Related editions

  • GLB Global Systems
  • GS-04 Health and One Health
  • GS-03 Food and Agrifood Systems
  • XT-05 Genomics and Gene Editing
  • SR-08 Health Security, One Health and Biosecurity
  • XT-01 Artificial Intelligence and Agentic Systems

8.5Biosecurity and governance watch

The nearest governance test is whether screening and oversight keep pace with design tools. Frameworks exist, and their status and implementation differ by jurisdiction.

49recommendations

US commission report, 202514

90days

deadline in the 2025 order for a revised screening framework26

2022framework

WHO global guidance on dual-use life sciences21

Table 8.5State at baseline
घटकस्थितीपुरावास्थिती
Screeninga 2025 study found tools often missed redesigned sequences; patches helped13नोंदवलेले
US framework2024 framework; 2025 order; not updated by September 2026 per CRS252627नोंदवलेले
EUBiotech Act proposal of 16 December 2025 with biodefence measures2228नोंदवलेले
जागतिकWHO guidance, CBD decisions, OECD papers, Cartagena Protocol18202135नोंदवलेले

Couplings

  • DAT → BIO sequence data
  • GOV → SEC screening rules
  • GOV → TRD export controls

Evidence to bind in 2027

  • screening coverage by provider
  • text of the current US framework

Related editions

  • GLB Global Systems
  • GS-04 Health and One Health
  • GS-03 Food and Agrifood Systems
  • XT-05 Genomics and Gene Editing
  • SR-08 Health Security, One Health and Biosecurity
  • XT-01 Artificial Intelligence and Agentic Systems

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
  2. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
  3. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
  4. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  5. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
  6. 43Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017 (record read via Crossref). American Association for the Advancement of Science, Washington. Observation year 2017. Accessed 2026-11-05.back
  7. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  8. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
  9. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
  10. 37McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020 (executive summary read; no figure used). McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-05.back
  11. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
  12. 36International Organization for Standardization (ed.), ISO 20688-2:2024, Biotechnology, Nucleic acid synthesis, Part 2: Requirements for the production and quality control of synthesised gene fragments, genes, and genomes (approved 15 March 2024; catalogue record and scope read via a national standards store). ISO, Geneva. Observation year 2024. Accessed 2026-11-05.back
  13. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
  14. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
  15. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
  16. 26The White House (ed.), Executive Order 14292 of 5 May 2025, Improving the Safety and Security of Biological Research, Federal Register 2025-08266, 8 May 2025 (text read; section 4(b) gives OSTP 90 days to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening). Office of the Federal Register, Washington. Observation year 2025. Accessed 2026-11-05.back
  17. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
  18. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  19. 25National Science and Technology Council, Fast Track Action Committee on Synthetic Nucleic Acid Procurement Screening (ed.), Framework for Nucleic Acid Synthesis Screening (version 1 April 2024, revised September 2024; framework document read). Office of Science and Technology Policy, Washington. Observation year 2024. Accessed 2026-11-05.back
  20. 27Congressional Research Service (ed.), Artificial Intelligence and Biosecurity Issues, CRS In Focus IF13269, 16 July 2026, updated 3 August and 15 September 2026 (all three versions read; the July version states that CRS could not determine whether the 2024 policy and the 2024 screening framework had been revised or replaced; the September update states that a July 2026 policy replaced the 2024 dual-use research policy and that OSTP had not updated the 2024 screening framework). Library of Congress, Washington. Observation year 2026. Accessed 2026-11-05.back
  21. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
  22. 28European Commission (ed.), Proposal for a Regulation on establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health (European Biotech Act), COM(2025) 1022 final, 2025/0406 (COD), Strasbourg, 16 December 2025 (proposal text read from the copy transmitted to the Austrian Parliament; health biotechnology investment pilot with the European Investment Bank Group; 12-month extension of the supplementary protection certificate; chapter on biodefence and preventing biotechnology misuse). European Commission, Brussels. Observation year 2025. Accessed 2026-11-05.back
  23. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
  24. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
  25. 35Secretariat of the Convention on Biological Diversity (ed.), The Cartagena Protocol on Biosafety to the Convention on Biological Diversity (protocol page read; adopted 29 January 2000; in force since 11 September 2003; governs living modified organisms). CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-05.back

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • Print

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF116 pages1.1 MBTagged, with bookmarks

      SHA-256 639c56cefb1949003c7c12afb373872ca06a7a9d2636ed3a03036421f5a0667e

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF124 pages1.1 MBTagged, with bookmarks

      SHA-256 809ea48a7122779a508bafef6382f20f37c4aec32bc811e35c132e78757714e8

  • Web edition

  • Data bundle

    • Indicators, CSV

      21 indicators with unit, year, status and source

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.csv2 KB

      SHA-256 ad80b1f5ddbd91cc3df1a06ae20fc038c8db1504b94d5d927e92cf4654cd1ef9

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.json3 KB

      SHA-256 42ed0ca7518f347165dbd95fe4869ad99cc319a622d910a46b91989f1f5b7e08

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-findings.csv4 KB

      SHA-256 1adaa8152308fb73ac5dd085a986cd24ce190e4728716aa4ff4a1b50a4e68f87

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 ea099771745b82b9d4f32643f1660d265a4d736b13c87edd7f1d406f3f019d07

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 17ed68ee662c0db11b3426eaeb65535f5fd14473a85160734886ccf70a44423b

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 0b1b02fec9505a958f1baaab6932ca483182ef925f5b68fadb22734159e1daea

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 8: Systems in depth. In Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

अहवालयोगदान द्या

Send evidence or a correction on Synthetic Biology and Bioengineering.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology
Contribution form · reports.contribution.gcri

वैयक्तिक डेटा, संवेदनशील पायाभूत सुविधांचा तपशील किंवा सामायिक करण्याचा तुम्हाला अधिकार नसलेले काहीही कधीही पाठवू नका. योगदानाचे वापरापूर्वी पुनरावलोकन केले जाते; ते पाठवल्याने कोणतेही लेखकत्व किंवा संपादकीय अधिकार मिळत नाहीत, आणि प्रायोजकत्वाने कधीही निष्कर्ष विकत घेता येत नाही.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

Your role here

What you can do from this page.

  • ReaderFound an error? Every correction is public.Corrections log
  • ContributorSend evidence, data or a correction to this desk.Contribute
  • ReviewerReview for this desk; verified reviews are credited.Become a reviewer
  • Editor, steward or boardQueues, decisions and production are in the workspace.My workspace